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Dendritic cells (DCs) are essential regulators of im-
mune responses; however, transcriptional mecha-
nisms that establish DC lineage commitment are
poorly defined. Here, we report that the PU.1 tran-
scription factor induces specific remodeling of the
higher-order chromatin structure at the interferon
regulatory factor 8 (Irf8) gene to initiate DC fate
choice. An Irf8 reporter mouse enabled us to pinpoint
an initial progenitor stage atwhichDCs separate from
other myeloid lineages in the bone marrow. In the
absence of Irf8, this progenitor undergoes DC-to-
neutrophil reprogramming, indicating that DC
commitment requires an active, Irf8-dependent
escape from alternative myeloid lineage potential.
Mechanistically, myeloid Irf8 expression depends
on high PU.1 levels, resulting in local chromosomal
looping and activation of a lineage- and develop-
mental-stage-specific cis-enhancer. These data
delineate PU.1 as a concentration-dependent rheo-
stat of myeloid lineage selection by controlling long-
distance contacts between regulatory elements and
suggest that specific higher-order chromatin remod-
eling at the Irf8 gene determines DC differentiation.INTRODUCTION
During myelopoiesis, self-renewing hematopoietic stem cells
(HSCs) differentiate into broadly myeloid-committed progenitors
(common myeloid progenitors [CMPs]), which further differen-
tiate into two major branches: polymorphonuclear phagocytes,
comprising granulocytes as well as mast cells, and mononuclear
phagocytes, comprising monocytes, macrophages, and den-
dritic cells (DCs) (Hume, 2008; Geissmann et al., 2010; Liu and
Nussenzweig, 2010; Kushwah and Hu, 2011). Although the sep-
aration process of granulocytes frommonocytes is relatively wellCstudied, it is poorly understood how myeloid precursors specify
into DCs. DCs are a heterogeneous cell population with a critical
role in immune response and self-tolerance (Steinman andCohn,
1973; Merad and Manz, 2009). In the current model, DCs are re-
plenished from macrophage-DC progenitors (MDPs) harboring
both macrophage and DC potential (Fogg et al., 2006; Geiss-
mann et al., 2010). MDPs are thought to directly yield common
DC progenitors (CDPs) (Onai et al., 2007). CDPs are a source of
both conventional DCs (cDCs) and plasmacytoitic DCs (pDCs).
A number of transcription factors, such as PU.1, SpiB, Tcf4
(E2-2), Batf3, Id2, and Irf8 (also known as interferon consensus
sequence binding protein [ICSBP]) have been implicated in DC
development (Watowich and Liu, 2010; Carotta et al., 2010;
Schotte et al., 2004; Cisse et al., 2008; Hildner et al., 2008;
Hacker et al., 2003). However, it is currently unknown if and
how these factors drive the initiation of DC commitment from
CMPs. Therefore, we aimed to decipher transcriptional mecha-
nisms initiating DC fate selection. For this purpose, we chose
to explore the molecular function and transcriptional regulation
of the Irf8 gene. Irf8–/– mice have profoundly depleted pDCs
and CD8a+ cDCs (Tsujimura et al., 2002, 2003b; la Sala et al.,
2009) but generate more neutrophils and develop a syndrome
that resembles human BCR-ABL+ chronic myeloid leukemia
(Holtschke et al., 1996; Schiavoni et al., 2002; Tsujimura et al.,
2003a; Ginhoux et al., 2009). Moreover, mutations inactivating
the IRF8 DNA binding domain have recently been shown to
cause human DC immunodeficiency (Hambleton et al., 2011).
Here, we generated Irf8 reporter mice and identified the pro-
genitor stage at which DC lineages separate from alternative
myeloid lineages.We show that Irf8 is required for the production
of this progenitor and reveal that the initiation of Irf8 expression is
controlled by PU.1-induced higher-order chromatin remodeling.RESULTS
Irf8 Separates the Early DC from Alternative Myeloid
Lineage Programs
Irf8–/– mice lack CD8a+ cDCs and pDCs but maintain normal
CD11b+ cDCs, as has been reported previously (Figures S1Aell Reports 3, 1617–1628, May 30, 2013 ª2013 The Authors 1617
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Figure 1. Irf8 Expression Is Required for
Transcriptional Identity of Early DC Progen-
itors
(A) The Cx3cr1GFP reporter allele was introduced
into the Irf8–/– background, and Cx3cr1GFP+
against c-kit in LinSca-1IL7Ra-gated BM cells
was analyzed by FACS.
(B) Total numbers of indicated cell populations
of Irf8+/+::Cx3cr1GFP/+ and Irf8–/–::Cx3cr1GFP/+
mice are shown ± SD, n = 3–5 each. LSKs were
LinSca1+c-kit+ cells, GMP* were LinSca1c-
kit+CD34+FcyRII/IIIhighCx3cr1-GFP, CMP* were
LinSca1c-kit+CD34+FcyRII/IIIlowCx3cr1-GFP.
(C and D) FACS of MDP-derived cells after 7 days
in methylcellulose cultures with 10 ng/ml GM-CSF
and 40 ng/ml IL-4. We plated 1,000 flow-sorted
MDPs and pooled colonies for analysis. *, p %
0.05; **, p % 0.005; ***, p % 0.001; n.s., not sig-
nificant; n = 3 each.
(E) Heat maps showing downregulated (yellow) or
upregulated (blue) genes in MDPs*
(LinSca1IL7Rac-kithighM-CSFR+) of Irf8–/–
mice. Differentially expressed geneswere grouped
into DC, neutrophil, monocyte, or shared DC and
monocyte signature genes, as indicated by the
color code on the right side. For detailed informa-
tion about signature genes, see Experimental
Procedures, Figure S1F, and Tables S1–S5.
(F) Relative distribution of upregulated myeloid
signature gene groups in Irf8–/– and in Irf8+/+
MDP*s.
(G) A density plot showing log2 of fold changes of
probe hybridization of Irf8–/– versus Irf8+/+ MDP*
progenitors for all DC, neutrophil, and monocyte
signature genes. A right shift indicates higher
expression in Irf8–/– progenitors, and a left shift
indicates lower expression.and S1B) (Tsujimura et al., 2002, 2003b; la Sala et al., 2009). To
pinpoint the differentiation stage at which Irf8 is required during
DC development, we introduced the Cx3cr1GFP reporter into the
Irf8–/– background, which was shown to mark MDPs as the initi-
ation stage of mononuclear phagocyte commitment (Jung et al.,
2000; Fogg et al., 2006). Whereas Lin/Sca-1+/c-kit+ cells (LSKs)
and granulocyte and macrophage progenitors (termed GMPs* in
order to indicate that they are Cx3cr1) were normal in Irf8–/–
mice, CMPs* (also Cx3cr1) and CDPs were reduced (Figures
1A, 1B, and S1C). However, surprisingly, the Cx3cr1 reporter re-
vealed a profoundly expanded MDP population. We confirmed
this expansion by using M-CSFR as a second marker for the
identification of MDPs (termed MDPs* in order to distinguish
them from Cx3cr1+ MDPs) because M-CSFR expression has
been shown to overlap with Cx3cr1GFP expression (Waskow
et al., 2008) (Figure S1D). Next, we explored the functional po-1618 Cell Reports 3, 1617–1628, May 30, 2013 ª2013 The Authorstential of Irf8–/– MDPs by performing
in vitro culture experiments. Irf8–/– MDPs
were unable to produce DCs but gave
rise to normal macrophage progeny (Fig-
ures 1C, 1D, and S1E).
To address whether Irf8 affects MDP
fate by skewing transcriptional lineageprograms, we isolated MDPs* from Irf8+/+ and Irf8–/– mice for
genome-wide expression profiling. In the Irf8–/– progenitors,
the expression of 104 genes was increased, and the expression
of 117 genes was decreased by more than 2-fold (p < 0.05).
Unbiased categorization of the differentially expressed genes
for different phagocyte lineage-associated gene signatures
(Figure S1F and Tables S1–S4) revealed that the Irf8+/+ progen-
itors expressed many DC and/or macrophage genes but few
neutrophil genes (Figures 1E and 1F). A loss of Irf8 reversed
this distribution in that the expression of DC and shared DC
and macrophage genes were reduced, but the expression of
neutrophil genes was enhanced. Notably, Irf8 deletion had only
minimal effects on macrophage gene expression. Moreover,
analysis of the expression of the entire signature gene sets within
the Irf8+/+ and Irf8–/– progenitors revealed that Irf8 deficiency re-
sulted in an overall weaker expression of the DC signature,
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Figure 2. Generation and Validation of Irf8-
VENUS Reporter Mice
(A) A schematic map of the genomic PAC clone
containing base pairs 123,197,900–123,308,928
of murine chromosome 8 (assembly version
NCBI37/mm9), which includes the Irf8 gene. An
ires-VENUS cassette was inserted in the Irf8 30
untranslated region and a 2.2 kb fragment con-
taining the 50 kb enhancer was flanked by loxP
sites (black arrowheads). The Irf8 gene exon
structure (black boxes), the transcription start site
(TSS), and the orientation of transcription (arrow)
are indicated.
(B) Left, the distribution of VENUS expression in
the BM of transgenic mice (line 88). Right, protein
from flow-sorted VENUS (neg.) and VENUS+
(pos.) fractions were subjected to western blotting
and probed with antibodies specific to the indi-
cated proteins.
(C) Quantitative RT-PCR (qRT-PCR) showing
mean Irf8 mRNA expression values ± SD
in peripheral blood neutrophils (CD11b+Ly6C+M-
CSFR) and B cells (B220+IgM+), and
splenic macrophages (CD11b+M-CSFR+), cDCs
(CD11c+B220), and pDCs (CD11c+B220+) all
sorted from nontransgenic mice.
(D) VENUS expression in Irf8VENUS+ transgenic
mice (red) and nontransgenic littermates (shaded)
derived from line 88. Cell populations were gated
as in Figure 2C with the addition of BM erythro-
cytes (Ter119+). The analysis was performed four
times with similar results. Mean fluorescence in-
tensity (MFI) is given for VENUS expression of
indicated populations.
See also Figure S2.a stronger expression of the neutrophil signature, and a largely
unchanged expression of themacrophage signature (Figure 1G).
Among the Irf8-controlled target genes were transcription fac-
tors (e.g., Klf9, Mef2d, and Runx2), chemokine receptors (e.g.,
Ccr1and Ccr2), and interferon- and toll-like-receptor-associated
genes (e.g., Ifngr1 and Ly86) as well as metalloproteinases (e.g.,
Mmp8) (Table S5).
We conclude that Irf8 is important for MDP transition to the
CDP by orchestrating the shift of neutrophil-to-DC gene expres-
sion programming. Irf8 deficiency did not change the MDP
macrophage program, indicating that Irf8 also acts as a tran-
scriptional separator of the DC from macrophage potential.
Tracing Irf8 Expression by Generation of Reporter Mice
Because the data showed that Irf8 ablation functionally and tran-
scriptionally separated DC frommacrophage potential of MDPs,
we reasoned that tracing Irf8 expression at the single-cell level
would make the identification of earliest DC-committed progen-
itors possible. Therefore, we engineered an Irf8 reporter mouseCell Reports 3, 1617–162by isolating a phage artificial chromo-
some (PAC; Mouse PAC Library
RPCI-21 296K2) comprising 130 kb of
chromosome 8, including all Irf8 exons
with flanking sequences of approximately81.3 kb 50 and 28.3 kb 30. A reporter cassette with an internal
ribosomal entry site linked to a VENUS yellow fluorescence
marker (ires-VENUS) was inserted into the 30 untranslated region
of Irf8 exon 9 (Figure 2A), resulting in the expression of a wild-
type (WT) Irf8 protein and the VENUS reporter from a bicistronic
messenger RNA (mRNA). In addition, we inserted loxP sites
around a cis-regulatory element 50 kb upstream of the Irf8 tran-
scription start site (see below) to enable its conditional removal
from the PAC. We generated stable transgenic lines from three
independent founder mice (lines 52, 87, and 88) with complete
integration of a structurally intact PAC DNA in two, three, and
four copies, respectively (Figures S2A–S2C). Importantly, the
PAC transgenes neither enhanced Irf8 expression overWT levels
nor caused any detectable phenotypic abnormalities (Figures
S2D and S2E).
Next, we separated bone marrow (BM) cells from the PAC
transgenic animals into VENUS+ and VENUS fractions using
fluorescence-activated cell sorting (FACS) and analyzed Irf8
expression (Figures 2B and S2F). Both Irf8 mRNA and protein8, May 30, 2013 ª2013 The Authors 1619
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Figure 3. Characterization of Irf8VENUS+
Myeloid Progenitors
(A) FACS of lineage negative (Lin) IL7Ra (upper
left) and LinIL7Ra+ (lower left) BM cells of an
Irf8VENUS+ transgenic mouse (line 88). Progenitor
populations in the indicated gates were analyzed
for VENUS expression. Red histograms represent
transgenics, and shaded histograms represent
nontransgenic controls. All plots are representa-
tive of four mice.
(B–D) Characterization of FACS-sorted Irf8VENUS+
MPs (LinSca1IL7Rac-kit+Irf8-VENUS+).
(B) May-Grunwald-Giemsa stain of Irf8VENUS+
MPs. The scale bar represents 20 mm.
(C) Analyses of the cell-cycle status of
Irf8VENUS+ MPs.
(D) A representative bar graph indicating the total
numbers of flow-gated Irf8VENUS+ MPs in marrow
of long bones (BM), spleen (SP), inguinal lymph
nodes (LN), and peripheral blood (PB) of trans-
genic mice (line 88). Data are represented as
mean ± SD.
(E) c-kit versus Irf8-VENUS FACS profiling
of sorted Irf8VENUS MP (LinSca1IL7Rac-
kit+FcyRII/III+Irf8-VENUS) and Irf8VENUS+ MP
(LinSca1IL7Rac-kit+FcyRII/III+Irf8-VENUS+)
in vitro at 0 hr and 24 hr in the presence of 10 ng/ml
IL3, 10 ng/ml IL6, and 50 ng/ml SCF. An FcgRII/III+
gate has been added here to avoid cell-sorting
contaminations with LSKs.
See also Figure S3B.
(F) Analysis of Irf8-VENUS expression in indicated
BM populations from Cx3cr1GFP::Irf8VENUS double
(red histograms) or Cx3cr1GFP single transgenic
(shaded histograms) mice. Cell gates were
LinSca1IL7Rac-kit+Cx3cr1GFP forCx3cr1negative
MPs, LinSca1IL7Rac-kithighCx3cr1GFP+ for
MDPs, and LinSca1IL7Rac-kitlowM-
CSFR+Cx3cr1GFP+ for CDPs (Liu et al., 2009). We
analyzed three mice of each genotype.were restricted to VENUS+ cells, indicating that the PAC re-
ported Irf8 expression with high stringency. Moreover, the line-
age-specific expression pattern of the VENUS reporter closely
paralleled endogenous Irf8 expression (Figures 2C, 2D, S2G,
and S2H). Hence, the reporter mice properly reflected in vivo
Irf8 gene expression.
The Irf8VENUS Reporter Marks a Subpopulation of the
MDP
Next, we analyzed Irf8 reporter expression in early hematopoiet-
ic precursors. HSCs, multipotent progenitors (MPPs), and com-
mon lymphoid progenitors (CLPs) had uniform VENUS levels,
indicating that all these cells expressed Irf8 (Figures 3A and
S3A). In contrast, only a small subset of myeloid progenitors
(MPs) expressed VENUS (representing 0.03% of all nucleated
BM cells). This subset (designated Irf8VENUS+ MPs) was
comprised of proliferating cells of typical undifferentiated pro-
genitor phenotype that were essentially restricted to the BM (Fig-1620 Cell Reports 3, 1617–1628, May 30, 2013 ª2013 The Authorsures 3B–3D and S3B). Irf8VENUS MPs gave rise to Irf8VENUS+
MPs in short-term culture assays, but not the other way around,
indicating that there is a lineage relationship between both pop-
ulations, Irf8VENUS+ MPs being downstream of this relationship
(Figure 3E).
Next, we explored the relationship between Irf8VENUS+ MPs
and Cx3cr1GFP+ MDPs by crossing Irf8VENUS with Cx3cr1GFP
mice. Whereas all Cx3cr1GFP myeloid progenitors were
VENUS and allCx3cr1GFP+ CDPswere VENUS+, approximately
half of theCx3cr1GFP+MDPpopulation expressed the VENUS re-
porter (Figure 3F). Thus, the MDP comprises two subfractions
that can be separated on the basis of Irf8VENUS expression.
Irf8VENUS+ MPs Are Early DC-Restricted Precursors
To evaluate the differentiation potential of Irf8VENUS+ MPs, we
performed transplantation experiments in mice. We injected
25,000 FACS-sorted Irf8VENUS+ or Irf8VENUS MPs (Figure 4A,
S4A, and S4B) or, as a control, 25,000 CDPs (all CD45.2+), into
CCD11c
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Figure 4. Irf8VENUS+Myeloid Progenitors Are
Early cDC Precursors
(A) The experimental strategy of myeloid progeni-
tor transplantation. Initial gating of Irf8VENUS MPs
was extended by gating on FcgRII/III+ cells to
avoid cell-sort contamination with HSCs.
See also Figure S3B.
(B) FACS of CD45.2+ donor-derived splenocytes
and BM cells 11 days after intravenous
transplantation with Irf8VENUS+ MPs
(LinSca1IL7Rac-kit+FcyRII/III+Irf8-VENUS+),
Irf8VENUS MPs (LinSca1IL7Rac-kit+FcyRII/
III+Irf8-VENUS), or CDPs (LinSca1c-kitlowM-
CSFR+Flt3+) into sublethally irradiated (6 Gy)
recipient mice. Results are representative of five
independent experiments for a total number of
eight CDP- (average cells per recipient = 500
spleen, 200 BM), 12 each Irf8VENUS+ MP- (average
cells per recipient = 1,000 spleen, 300 BM), or
Irf8VENUSMP- (average cells per recipient = 2,000
spleen, 1,000 BM) transplantedmice, respectively.
Mean values of at least five mice ± SD are given.
(C) FACS of CD45.2+ donor-derived splenocytes
and BM cells 7 days after intravenous trans-
plantation with Irf8VENUS+ MPs or Irf8VENUS MPs
into no irradiated recipient mice.
See also Figure S4.the tail veins of sublethally irradiated congenic mice (CD45.1+)
and analyzed their cellular progeny 11 days posttransplantation.
Irf8VENUS+ MPs gave rise to 1%–2% nucleated cells in the
spleens and 0.3% in the BM of recipients (Irf8VENUS MPs,
3% in spleens and 0.9% in BM; CDPs, 0.8% in spleens and
0.1% in BM). In the spleen, we exclusively detected
CD11c+MHCII+B220 cDC progeny of Irf8VENUS+ MPs, whereas,
in the BM, we also found donor-derived CD11c+B220+ pDCs
(Figure 4B). Irf8VENUS+ MPs completely lacked any
CD11cB220+ B cell, Ly6c+M-CSFR neutrophil, or Ly6c+/M-
CSFR+ monocyte and macrophage potential. Irf8VENUS MPs
differentiated into neutrophils, monocytes and macrophages,
cDCs and pDCs, but not into B cells. CDPs produced cDCs
and pDCs as described before (Onai et al., 2007). Both CD8a+
and CD8a pDCs were produced by CDPs and Irf8VENUS+ MPs
at similar frequencies, suggesting that both progenitors are
within the same differentiation pathway (Figure S4C). Further-
more, we confirmed a lack of Irf8VENUS+MPdifferentiation poten-
tial into macrophages by the absence of F4/80, MOMA-1,
MARCO, and SIGNR1 expression on VENUS+ donor-derived
splenocytes (Figure S4D). Moreover, we corroborated DC-Cell Reports 3, 1617–162restricted differentiation potential of
Irf8VENUS+ MPs by transplantation into
nonirradiated recipient mice and analysis
after 7 days (Figure 4C).
To further determine the DC differentia-
tion potential of Irf8VENUS+ MPs, we per-
formed in vitro culture experiments in
the presence of GM-CSF and FLT3 ligand
(FLT3L) for 7 days. Supporting the in vivo
results, Irf8VENUS+MPs almost exclusivelyproduced CD11c+MHCII+ DCs with a typical spread-out
morphology, whereas Irf8VENUS MPs produced much fewer
DCs (Figures S4E–S4G).
Altogether, these experiments demonstrated that the Irf8VENUS
reporter marked an early BM progenitor with exclusive DC differ-
entiation potential.
A Distal Enhancer Drives Myeloid Irf8 Promoter Activity
The data above indicated that the onset of myeloid Irf8 expres-
sion phenotypically marks and functionally determines the
developmental stage of DC lineage selection in the BM. To
decipher regulatory mechanisms preceding DC fate choice, we
explored how Irf8 expression is initiated. Given that lineage-spe-
cific gene expression is primarily orchestrated through gene-
distal regulatory elements (Heinz et al., 2010), we computation-
ally identified a number of different evolutionarily conserved
noncoding sequences (CNSs) upstream of Irf8 (Figure 5A).
We performed reporter assays in stably transfected
RAW264.7 myeloid cells and NIH 3T3 fibroblasts to test whether
these CNSs were able to enhance the activity of the Irf8 proximal
promoter in chromatin context. Both the Irf8 promoter alone and8, May 30, 2013 ª2013 The Authors 1621
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Figure 5. A Specified cis Enhancer Drives
Irf8 Expression in MDPs
(A) mVista representation (http://genome.lbl.gov/
vista/index.shtml) of DNA sequence conservation
of the Irf8 locus. The panels indicate conservation
of the mouse genomic region versus the corre-
sponding region in humans, cats, and opossums.
Shown are regions of at least 50% conservation
(y axis), exons (blue), and noncoding conserved
regions (pink). Positions of CNS regions are indi-
cated and labeled on the basis of their distance to
the Irf8 TSS (top).
(B) Shown are pXP2-based luciferase (luc) reporter
activities in Irf8-expressing RAW264.7 cells and
Irf8-nonexpressing NIH 3T3 fibroblasts stably
transfected with the indicated reporter plasmids.
Depicted are the mean values ± SD of at least six
independent bulks for each construct. The
average activity of pXP2-Irf8prom-luc was set to 1.
(C) The top panel shows a schematic diagram of
the loxP-flanked 2.2 kb Irf8-VENUS PAC fragment
containing the 50 kb enhancer before (+) and
after (D) its CRE-mediated excision. The bottom
panel shows PCR genotyping of tail genomic DNA
from the indicated mice (transgenic line 88). PCR
reactions with primer pairs detecting the upstream
(loxP1) or downstream loxP site (loxP2) before
excision, or the fused loxP1-loxP2 sites (D) after
excision are depicted.
(D) FACS histograms of the indicated hematopoi-
etic populations from Irf8VENUS50kb+ (red) and
Irf8VENU50kbD (blue) transgenic and nontransgenic
(shaded) mice (all from transgenic line 88). HSC
and MPP were LinSca1+c-kit+ cells, MDP*
were LinIL7RaSca1ckithighM-CSFR+, splenic
CD8a+ cDCs were CD11c+CD8a+B220, pDCs
were CD11c+B220+, and splenic B cells were
B220+IgM+. Data are representative of four ani-
mals of each genotype.
(E) MFI values of the indicated populations from
Irf8VENUS50kbD mice shown as percentage of
Irf8VENUS50kb+ values.
(F) Deletion of the 50 kb enhancer impairs the
capacity of the Irf8 PAC to rescue the DC pro-
genitor phenotype of Irf8/ mice. MDP* fre-
quencies in BM of Irf8+/+, Irf8/,
Irf8/:Irf8VENUS50kb+, or Irf8/:Irf8VENUS50kbD
mice. The percentage of living cells per mouse ±
SD is given for the indicated population.
See also Figure S5.the promoter in combination with the 38 kb or 16 kb CNSs
were unable to drive reporter gene expression. However, the
addition of the11 kb CNS led to a 20-fold increase in promoter
activity in RAW264.7 cells, and the addition of the 50 kb CNS
increased the activity 750-fold (Figure 5B). No enhancer function
was observed in NIH 3T3 cells.
The 50 kb Enhancer Controls Irf8 Expression in MDPs
In Vivo
Because the 50 kb CNS displayed the highest enhancer
activity in vitro, we tested whether this element was required
for Irf8 expression in vivo. We modified the Irf8VENUS reporter
PAC by flanking a 2.2 kb fragment containing the 50 kb CNS
with loxP sites and generated transgenic animals (see above).1622 Cell Reports 3, 1617–1628, May 30, 2013 ª2013 The AuthorsWe crossed two of these transgenic lines (87 and 88) with
CMV-cre deleter animals (Schwenk et al., 1995) to generate a
germline deletion of the 50 kb element (designated
Irf8VENUS50kbDmice) (Figure 5C). We confirmed proper excision,
copy number maintenance, and genomic integrity of the
Irf8VENUS50kbD transgenes in the resulting offspring (Figures
S5A–S5C).
Irf8VENUS50kbD mice demonstrated a tight cell-type- and
developmental-stage-specific requirement of the 50 kb
enhancer for Irf8 expression. Deletion of the 50 kb enhancer
decreased VENUS expression only mildly in HSCs and MPPs
(both included in the LSK fraction), B cells, and pDCs more
strongly in CD8a+ cDCs and most profoundly in MDPs* (Figures
5D, 5E, and S5D).
AB
C
M
ar
ke
r
-50 -38 -16 -11 ci
rc
le
 Irf8 promoter  
+ 
gD
N
A 
RAW264.7 
with ligase 
Irf8-PAC 
with ligase 
RAW264.7 
no ligase 
Irf8
-50 kb -38 kb -16 kb -11 kb 
N N 
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
MP 
0.004 
R
el
at
iv
e 
cr
os
sl
in
ki
ng
 fr
eq
ue
nc
y 
MDP* 
*** 
.  
.  
.  
.  
.  
.  
.  
.  
R
el
at
iv
e 
cr
os
sl
in
ki
ng
 fr
eq
ue
nc
y 
1.6 
n.d. 
0.2 
1.4 
0.4 
1.2 
0.6 
1.0 
0.8 
B cell pDC Mac MDP* cDC 
cutting   99.87    99.98   99.1     99.9    93.48 
efficiency (%) 
0.0 
Figure 6. Three-Dimensional Chromatin Structure Remodeling of
the Irf8 Locus
(A) Shown is 3C with RAW264.7 cells. Crosslinked chromatin was digested
with NcoI (N, each line represents an NcoI restriction site) and amplified by
nested PCR, as depicted at the top (bold arrows). Nonligated RAW264.7
chromatin served as a negative control, and randomly ligated NcoI Irf8-PAC
fragments were positive controls. PCR amplification of self-ligated NcoI Irf8
promoter chromatin fragments (circle) by two outside-facing primers anneal-
ing within the promoter anchor primers served as a digestion and ligation ef-
ficiency control. PCR amplification with two primers that annealed within the
NcoI50 kb enhancer genomic DNA (gDNA) fragment served as input control.
(B and C) q3C showing50 kb to Irf8 promoter spatial proximity in flow-sorted
cell populations. All data were normalized to total gDNA content within anNcoI
restriction fragment. Normalization to looping at the Gapdh locus as house-
keeping loop (Spilianakis et al., 2005) gave identical results. No-ligation con-
trols showed no interaction. Data from MDP* was set to 1. All cells were from
WT mice. Mean values ± SD are given.
(B) q3C showing 50 kb to Irf8 promoter spatial proximity in MDP*, but not in
M-CSFR MPs of the BM. Displayed results are representative for three ex-
periments with similar outcomes. ***, p% 0.001.
(C) q3C results show cell-type-specific proximity of the 50 kb fragment with
the Irf8 promoter. MDP*s from BM were compared to splenic B cells, pDCs,
cDCs, and macrophages. n.d., not detectable.
CNext, we explored the functional relevance of the 50 kb
element for MDP* formation by introducing the Irf8VENUS50kb+
or Irf8VENUS50kbD transgenes into the Irf8-deficient background.
Importantly, the Irf8VENUS50kb+ transgene completely restored
normal Irf8–/– MDPs* (Figure 5F). In contrast, the Irf8VENUS50kbD
transgene had 54% less efficient restoration capacity.
Altogether, genetic experiments in mice provide in vivo evi-
dence for a specific role of the 50 kb element in the control
of Irf8 expression in MDPs.Higher-Order Chromatin Structure Remodeling at the
Irf8 50 kb Enhancer
An important question was why the50 kb enhancer had such a
specific effect on Irf8 expression in DC progenitors. We ad-
dressed this issue by exploring the higher-order chromatin struc-
ture at the Irf8 locus using chromosomal conformation capturing
(3C). First, we screened the Irf8 upstreamCNSs for spatial three-
dimensional contacts with the proximal Irf8 promoter region in
RAW264.7 cells. We observed that the 50 kb enhancer and
the16 kbCNS, but not the38 or11 kbCNSs, were in spatial
proximity with the Irf8 promoter, thus indicating a specific acti-
vating chromatin looping architecture at the Irf8 locus
(Figure 6A).
To corroborate the observation that the 50 kb enhancer-to-
Irf8 promoter contact existed in primary cells, we used a quanti-
tative 3C (q3C) protocol on FACS-sorted cells. Indeed, the
50 kb enhancer was found in physical contact with the Irf8 pro-
moter in MDPs* but is not found to be in physical contact in MPs
(Figure 6B). Moreover, comparison across cell types demon-
strated that 50 kb enhancer contact with the Irf8 promoter
was strongest in MDPs* but decreased thereafter in their cDC,
macrophage, and pDC progeny and was undetectable in B cells
(Figure 6C). Thus, the 50 kb enhancer was brought into phys-
ical contact with the Irf8 gene by tightly controlled remodeling
of its higher-order chromatin structure. The dynamics of this re-
modeling closely paralleled the onset of Irf8 expression duringell Reports 3, 1617–1628, May 30, 2013 ª2013 The Authors 1623
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Figure 7. PU.1 Expression Induces 50 kb
Irf8 Enhancer Activity and Chromatin Re-
modeling
(A) Two adjacent sequence-conserved PU.1
bindingmotifs are located in the50 kb element of
vertebrates.
(B) The 50 kb element is transcriptionally active
and binds PU.1 in cDCs, but not in B cells. ChIP
results in the indicated cell types with antibodies
recognizing PU.1, acetylated histone H3K9
(H3K9ac), and IgG as control are shown. Specific
primers that amplify the50 kb region by real-time
PCR were used. Values normalized to input are
given ± SD of three different reactions.
(C and D) Reporter assay in RAW264.7 cells stably
transfected with the pXP2-50kb-Irf8prom-luc
luciferase construct are shown.
(C) Luciferase constructs were carrying mutations
in the PU.1 binding sites (GGAA to GCGC) of the
50 kb fragment. Shown are the mean values ±
SD of at least six different cell clones for each
construct, p = 0.001 (PU.1A) and p = 0.005
(PU.1B). Activity of the nonmutated construct was
set to 100%.
(D) Cells were either mock transfected or transiently
transfected with constructs expressing shRNAs
againstPU.1ora scramblecontrol, alongwithaGFP
marker to allow flow cytometric sorting of trans-
fectedcells.Themockcontrolwassetas100%.The
experiment was repeated twice with similar out-
comes. Mean values ± SD are given; p = 0.005.
(E) q3C shows increased interaction frequency of
the 50 kb fragment with the Irf8 promoter 8 hr
after 4-hydroxytamoxifen (OHT) induction of PU.1
expression in PU.1–/–ERT-PU.1 cells (PU.1ER).
n = 3 experiments with similar outcomes. All data
were normalized as in Figure 6B. Interaction in
PU.1/ERT-PU.10 hr induced was set to 1. Mean
values ± SD are given; p = 0.003.
(F) qRT-PCR of Irf8 and PU.1 messenger RNA
(mRNA) expression in FACS-sorted MPs and
MDPs* gated as in Figure 6B. Displayed are the
mean values ± SD of two biological replicates
each.
(G) qRT-PCR of Irf8 and PU.1 mRNA expression
in FACS sorted LinSca1c-kit+ myeloid
progenitors isolated from the BM of mice with a deleted upstream regulatory element (URE) of the PU.1 gene (Rosenbauer et al., 2004).
(H) Impaired q3C interaction frequency of the 50 kb fragment with the Irf8 promoter in PU.1-shRNA-transfected versus scramble-transfected RAW264.7 cells.
Displayed results are representative for two experiments with similar outcomes. All data were normalized as in Figure 6B. The value of RAW264.7scramle was set
to 1. Mean values ± SD are given.
(I) Relative distribution of CD11c+MHCII+ cells derived from Irf8/ and Irf8+/+ c-kit+ BM cells transduced with retroviruses expressing GFP alone, Irf8-GFP, or
PU.1-GFP. Cells were kept in liquid culture for 8 days with 100 ng/ml Flt3L and were gated on GFP-expressing cells for analysis. n = 3 replicates per condition
were analyzed.
**, p % 0.005 and ***, p % 0.001.myeloid differentiation and, thus, provided an explanation for the
specific effect of50 kb enhancer deletion on DC progenitors in
mice.
PU.1 Binding Is Necessary for 50 kb Enhancer Activity
and Induces Chromatin Remodeling
A computational motif search identified two directly adjacent
PU.1-binding consensus motifs that were highly conserved
among vertebrate species (Figure 7A). Indeed, PU.1 occupied
these sites in primaryDCsbut did not occupy these sites in B cells1624 Cell Reports 3, 1617–1628, May 30, 2013 ª2013 The Authors(Figure 7B). PU.1 occupancy was associated with cell-type-spe-
cific H3K9 acetylation, indicating a transcriptional regulatory ac-
tivity of the 50 kb element in DCs. In the RAW264.7 cell-line
model, mutations in either one of these PU.1-binding sites or
knockdown of PU.1 by small hairpin RNA (shRNA) diminished
50 kb enhancer activity as well as endogenous Irf8 expression
(Figures 7C, 7D, and S6A). Furthermore, activation of a 4-hydrox-
ytamoxifen (OHT)-responsivePU.1-ERT fusionprotein inaPU.1–/–
myeloid progenitor cell line (termed PU.1ER cells) revealed PU.1
as a direct activator of Irf8 expression (Figures S6B–S6D).
To investigate whether PU.1 controls chromatin looping of the
50 kb enhancer to the Irf8 promoter, we performed q3C assays
in PU.1ER cells and found that PU.1 induction rapidly led to a
marked increase in looping frequency (Figure 7E).
50 kb Enhancer Chromatin Structure Remodeling
Requires a High PU.1 Level
Intriguingly, although the expression of both Irf8 and PU.1
increased to similar levels in MDPs*, the expression of Irf8 was
absent in MPs, whereas the expression of PU.1 was low but
readily detectable in MPs (Figure 7F), suggesting that high
PU.1 levels are required to trigger Irf8 transcription. To directly
test this, we quantified Irf8 expression in myeloid progenitors
from PU.1 hypomorphic mice that expressed PU.1 at a 5-fold
lower level than the corresponding WT cells (Rosenbauer et al.,
2004). Indeed, these progenitors showed almost a complete
lack of Irf8 transcripts, indicating that the reduced PU.1 level pro-
vided by the hypomorphic alleles was insufficient for Irf8 expres-
sion (Figure 7G). In line with this, shRNA-mediated gradual
reduction of PU.1 levels in the RAW264.7 model impaired 50
kb enhancer-to-Irf8 promoter contact formation (Figure 7H).
Altogether, these data indicate that PU.1 can function as a con-
centration-dependent trigger of Irf8 chromatin remodeling and
transcription.
PU.1 Fails to Drive DC Differentiation in the Absence of
Irf8
PU.1 is known to induce DC differentiation (Carotta et al., 2010;
Guerriero et al., 2000). To test whether PU.1 requires Irf8 to
induce DC development, we transduced c-kit+ BM progenitors
from Irf8/ mice with retroviruses expressing either PU.1 or
Irf8 along with GFP from bicistronic mRNAs or with a retrovirus
expressing GFP only. GFP+ cells were sorted and cultured with
Flt3L to support generation of DCs. Ectopic PU.1 failed to drive
development of MHCII+CD11c+SirpaB220 cDCs and
MHCII+CD11c+B220+ pDCs of Irf8/ progenitors, whereas Irf8
restoration rescued the capacity to produce both DC popula-
tions (Figures 7I, S6E, and S6F). This result indicates that PU.1
requires the presence of Irf8 to induce DC differentiation.
DISCUSSION
DCs are related to, but clearly distinct from, macrophages
(Merad and Manz, 2009; Geissmann et al., 2010), and the iden-
tification of cellular precursors of the DC lineage has been the
focus of intense research (Ginhoux et al., 2009; Fogg et al.,
2006; Manz et al., 2001; Carotta et al., 2010; Liu et al., 2009;
Waskow et al., 2008). Taking advantage of a newly generated
Irf8 reporter mouse, we report a distinct Irf8-expressing subfrac-
tion of the MDP (Fogg et al., 2006). This Irf8VENUS+ population
had the exclusive capacity to differentiate into DCs, but not
into monocytes or macrophages, in vivo. Although the cDC po-
tential of Irf8VENUS+ MPs was strong, the pDC potential was
weaker than that of CDPs. One likely explanation for this differ-
ence could be that Irf8VENUS+ MPs require more time than
CDPs to fully replenish pDCs. This, along with their higher c-kit
level, supports the idea that Irf8VENUS+ MPs reside upstream of
CDPs. However, the question of whether Irf8VENUS+ MPs are aCseparate population or whether they overlap with the earliest
CDPs requires further investigation. In any case, the identifica-
tion of Irf8VENUS+ MPs as an initial DC precursor within the
formerly identifiedMDPpopulation is instrumental in deciphering
the earliest molecular events initiating DC development.
Irf8-reporter-based marking of this early DC stage is associ-
ated with functional Irf8 dependency in the production of DC
progenitors. MDPs isolated from Irf8–/– mice had maintained
macrophage and monocyte differentiation capacity but
completely lacked DC potential in vitro. A recent study sug-
gested that Irf8 is required for the production of DC progenitors
and for the restriction of GMP expansion (Becker et al., 2012). By
introducing theCx3cr1GFP reporter into Irf8/mice, we revealed
that Irf8 deficiency reduced DC development by impairing the
transition of MDPs into CDPs. In contrast, GMPs were not
affected. The early differentiation block in Irf8/ mice appears
surprising, given that not all DC populations are absent in these
animals. However, our data showed that some progenitors can
transit into the CDP stage even in the absence of Irf8. These cells
may be biased to replenish certain DCs. Alternatively; Becker
et al. (2012) have shown that Irf8/ progenitors are less able
to replenish all DC populations in chimeric mice, suggesting
that homeostatic proliferation may also contribute to the mainte-
nance of CD11b+ DCs in Irf8-deficient animals.
Irf8–/– MDPs showed a lower expression of DC-associated
genes but a higher expression of neutrophil-associated genes
and an unchanged expression of macrophage-associated
genes. This finding indicated that the initiation of DC differentia-
tion choice requires an active, Irf8-dependent shift from neutro-
phil-to-DC gene expression in MDPs. In light of these data, it
appears most likely that the excessive production of neutrophils
leading to the development of granulocytic leukemia in Irf8–/–
mice may be the result of this DC-to-neutrophil ‘‘conversion’’
of the MDP. It will be interesting to see whether a similar mech-
anism also underlies the development of IRF8-mutated human
DC immunodeficiency, which can be accompanied by high
neutrophil counts as well (Hambleton et al., 2011).
A chromatin-based mechanism driving the molecular commit-
ment of early myeloid progenitors toward DC differentiation has
remained elusive. Here, we were able to pinpoint a region
located 50 kb upstream of the Irf8 gene as the major enhancer
driving Irf8 expression during DC progenitor formation in vivo.
Deletion of the 50 kb enhancer from the engineered Irf8 PAC
led to reduced reporter gene expression in MDPs, but not in
stem cells, pDCs, or B cells. Accordingly, DC progenitor devel-
opment was impaired in the absence of the 50 kb enhancer.
Different models of how distal regulatory elements communi-
cate with proximal gene regulatory regions have been proposed
(Wittkopp and Kalay, 2012; Bulger and Groudine, 2011). One of
these models suggests that enhancers are placed in physical
proximity to promoters through chromosomal looping (Heer-
mann, 2011). Indeed, on the basis of 3C technology, there are
now a number of examples known that support the looping
model (Palstra et al., 2003; Tolhuis et al., 2002; Apostolou and
Thanos, 2008; Spilianakis et al., 2005; Ling et al., 2006). We
found that looping of the 50 kb enhancer to the Irf8 promoter
occurred with high specificity with regard to the lineage and
developmental stage and, at least in a cell-line model, requiredell Reports 3, 1617–1628, May 30, 2013 ª2013 The Authors 1625
PU.1 as a coordinator. Although it is not yet clear whether PU.1
controls Irf8 chromatin looping directly, our findings suggest a
concentration-dependent model in which high PU.1 amounts
are required to drive Irf8 locus looping and transcription. Such
a model is supported by the recent finding that high PU.1 levels
are also needed to drive Flt3 expression in cDC progenitors (Car-
otta et al., 2010). Although our retroviral transduction assays
have shown that PU.1 requires Irf8 as a downstream target to
drive DC development, Irf8 could not substitute PU.1 in DC dif-
ferentiation (see Figure 7A) (data not shown). Again, this is similar
to the inability of Flt3 to rescue PU.1-deficient DC production
(Carotta et al., 2010). Altogether, these results suggest that
PU.1 controls multiple independently actingmolecular pathways
to drive DC development. This idea is supported by our results
showing that PU.1 controls Flt3 expression independently of
Irf8 (data not shown).
In summary, we have isolated an initial Irf8+ DC progenitor. In
this progenitor, Irf8 transcriptionally organizes the separation of
the DC program from that of other myeloid lineages, including
the monocytic program. PU.1 induces Irf8 expression by remod-
elling its higher-order chromatin configuration to loop a distant
cis-enhancer into physical proximity to the Irf8 promoter.
EXPERIMENTAL PROCEDURES
Mice and Cell Lines
All mice in this research were studied on a C57Bl/6 background. C57Bl/6 wild-
typemice were fromCharles River Laboratories. Irf8/ andURE/mice were
generated as described before (Holtschke et al., 1996; Rosenbauer et al.,
2004). Irf8VENUS PAC reporter mice were generated by pronuclear injection
of the engineered murine Irf8-PAC (Figure S1A) into WT C57Bl/6 fertilized oo-
cytes. Injection was conducted at the Max Planck Institute of Molecular Cell
Biology and Genetics. PAC+ animals were identified by FACS and PCR
(primers are available on request). Three independent PAC lines were estab-
lished and used for this study. Two of these lineswere bred to CMV-Cre deleter
mice (Su et al., 2002), leading to the excision of the loxP-flanked 50 kb
element. All mouse experiments were approved by the local authorities ac-
cording to the German Federal Animal Protection Act. RAW264.7, NIH 3T3,
416B, PU.1–/–ERT-PU.1, and PU.1–/– cell lines were cultured as described
before (Leddin et al., 2011; Walsh et al., 2002).
Flow Cytometry and Cell Sorting
Single-cell suspensions from indicated organs were analyzed by flow cytom-
etry on a BD LSRFortessa cell analyzer (BD Biosciences). Cell sorting was per-
formed on a FACSAria (BD Biosciences) equipped with an UV laser. Prior to
flow sorting of BM precursors, lineage-associated cells were manually
depleted after being incubated with CD3, CD4, CD8a, B220, CD19, CD11b,
CD11c, and/or Gr-1. Nonspecific binding was reduced where applicable by
preincubation with unconjugated antibody to FcgRII/III (2.4G2). Propidium io-
dide was used for the exclusion of dead cells. Cell-cycle status was deter-
mined by staining with Hoechst 33342 stain according to standard protocols.
In Vitro Colony-Forming Assays
Flow-sorted cells (1 3 103) were seeded in MethoCult (M3234, STEMCELL
Technologies) in triplicate. Supplements were treated with M-CSF (10 ng/ml)
alone or a cocktail of SCF (50 ng/ml), IL-3 (10 ng/ml), IL-6 (10 ng/ml), and either
GM-CSF (10 ng/ml), FLT3 ligand (50 ng/ml or 100 ng/ml), or a combination of
both (all from Peprotech). Alternatively, MethoCult (M3334) supplemented with
SCF (50 ng/ml), IL-3 (10 ng/ml), IL-6 (10 ng/ml), and erythropoietin (3 U/ml) was
used. Individual colonies (defined as containing more than 50 cells) were
scored with an inverted light microscope 7–10 days after plating. For the ex-
amination of morphology, cells were centrifuged onto glass slides and stained
with May-Grunwald-Giemsa, as described before (Fogg et al., 2006).1626 Cell Reports 3, 1617–1628, May 30, 2013 ª2013 The AuthorsProgenitor Transplantation Assays
For progenitor transplantation assays, 25,000 flow-sorted progenitors
(Irf8VENUS+ MPs, Irf8VENUS MPs or CDPs, all CD45.2+) were transferred intra-
venously into sublethally irradiated (6 Gy) 4-week-old recipient mice and
analyzed 11 days later or, alternatively, were transferred intravenously into
nonirradiated 4-week-old recipient mice (CD45.1+) and analyzed after 7 days.
Microarrays
LinIL7RaSca1ckit+M-CSFR+ progenitors were sorted from BM of three in-
dependent pools of Irf8+/+ and Irf8/mice, respectively. Every pool consisted
of cells from three to four animals at the age of 8–12 weeks. Additionally,
monocytes and macrophages (CD11b+Ly6C+M-CSFR+), neutrophils
(CD11b+Ly6C+M-CSFR), and total DCs (CD19CD3eCD11c+) were sorted
from the spleens of three independent pools of C57Bl/6 WT mice, each con-
sisting of three animals at the age of 8–12 weeks. RNA was extracted accord-
ing to the RNeasy Micro Kit (QIAGEN) protocol. High-quality RNA (Rin > 8.9)
was assessed by employing the Agilent 2100 Bioanalyzer. For linear amplifica-
tion of RNA, a strategy of two rounds of reverse transcription followed by T7
promoter-dependent in vitro transcription was applied with the Ovation Pico
WTA System (NuGEN) according to manufacturer’s instructions. For each
sample, 10 mg of amplified RNA sample was labeled and hybridized in triplicate
to a 24-slide cartridge Affymetrix Mouse Genome 430 2.0 Array according to
the manufacturer’s instructions.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed employing the Low-
Cell# ChIP Kit (Diagenode). The antibodies used in this study included anti-
PU.1 (T-21X, Santa Cruz Biotechnology), anti-IgG (Millipore, 12-370), and
anti-acetyl-histone H3 (Millipore, 06-599). Immunoprecipitates were quantified
with SYBR Green quantitative PCR (qPCR) on a 7300 Real-Time PCR System
(Applied Biosystems). Results were calculated as percentage of the input sam-
ple, and nonspecific IgG control is shown. Primer sequences are available
upon request.
Chromosome Conformation Capturing
3C was essentially conducted according to Dekker et al. (2002). In brief, chro-
matin of 1 3 107 cells was crosslinked by a 10 min treatment with 5.4% form-
aldehyde followed by quenching with glycine and digestion with NcoI (New
England Biolabs; 800 U, treated overnight). A fraction was removed as a no-
ligation control; the remaining sample was diluted 45 times and religated
with T4 DNA Ligase (NE Biolabs). For the analysis of ex vivo populations 1 3
105 flow-sorted progenitor cells, we applied a protocol by Dostie and Dekker
(2007) and mademinor modifications according to Staber et al. (2013). 3Cma-
terial was analyzed by nested PCR or by qPCRwith a TaqMan probe spanning
the NcoI site between the Irf8promoter fragment and the 50kb enhancer.
Relative crosslinking frequencies were calculated after normalization to total
DNA content as quantified at the 50 kb enhancer site. Additionally, relative
crosslinking frequencies were calculated after normalization to chromosomal
looping at the Gapdh locus, as described before (Spilianakis et al., 2005).
qPCR reactions were performed in triplicate and each experiment was
repeated independently up to three times. Primers and probes were validated
employing the digested and religated Irf8-PAC DNA. Digestion efficiency was
calculated as in Hage`ge et al., (2007). Only samples with digestion efficiency
> 90% were used. Sequences are available upon request.
Cell Transfections and Luciferase Assays
Stably transformed reporter cell lines were generated by electroporation in
RAW264.7 and NIH 3T3 cells with a Gene Pulser Xcell (Bio-Rad). PvuI-linear-
ized reporter plasmids were coelectroporated with a plasmid carrying a
puromycin resistance gene. The cells were subsequently kept under puromy-
cin selection for 3 weeks. For the expression of firefly luciferase, 5 3 105 cells
of stably transformed pools or single cloneswere analyzed with the Dual-Lucif-
erase Reporter Assay System (Promega) according to the recommendations
of the manufacturer.
RAW264.7 cells were transfected with shRNA-GFP constructs (see Supple-
mental Information). GFP+ cells were sorted 48 hr after transfection, and
53 105 cells were analyzed with the Dual-Luciferase Reporter Assay System.
Statistical Analysis
Unpaired Student’s t test was carried out to determine the statistical signifi-
cance of experimental results. All experiments shown were replicated at least
two to three times with similar results, unless indicated differently in the figure
legends.
ACCESSION NUMBERS
Microarray data have been deposited in the Gene Expression Omnibus (GEO)
at accession number GSE45467. For microarray data processing, see Supple-
mental Information.
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